32 ASC leaders speaking at Becker s October ASC event discuss how the future of ASC consolidation might look while considering factors such as value-based care, private equity, patient safety, and payer contracts.
Cuptimize Announces 510(k) FDA Clearance of its New Proprietary Software Designed to Identify and Treat Spinopelvic Motion Abnormalities in Total Hip Replacement
Share Article BELLEAIR BLUFFS, Fla. (PRWEB) March 09, 2021 Cuptimize Inc., a medical device software company, focused on spinopelvic motion abnormalities, announced today that it has received FDA clearance for their latest software. The system provides a preoperative and intraoperative solution that relies exclusively on x-ray and requires no CT scan for the preoperative analysis module.
The Cuptimize solution allows hip surgeons to understand when the patient has a problem, determine cup placement to mitigate risk and have clear indications of when to use dual mobility implants. The system also integrates directly with intraoperative navigation solutions.